Scholars Central

Conference abstractPublished 18 Sep 2017

Neoepitopes as personalized cancer vaccines

Authors: Hakimeh Ebrahimi Nik

University of Connecticut School of Medicine, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

It is now well known that cancer is not only patient-specific but inherently specific to the single tumor itself. Some of new epitopes (neoepitopes), raised from tumor somatic mutations, are uniquely identifiable fingerprints by which immune system differentiate cancer from normal cells. Using the potential of neoepitopes to stimulate the adaptive immune response against tumor, this tool has been recently considered as putative personalized cancer vaccine. By means of a bona fide neoepitope which causes 100% tumor rejection in BALB/c fibrosarcoma tumor model, we revealed some of important challenges of neoepitope immunization. We observed that a successful neoepitope immunization depends on flanking sequences, length and dosing of the peptide as well as the organism age. Surprisingly, we found out that the current CD8 T cell responses are not sufficient to determine the efficacy of neoepitopes and the choice of adjuvants may have profound consequences on the course of cancer progression. These findings have strong implications for neoepitope-based human cancer immunotherapy.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Cancer Science & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalCancer Science & Therapy
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Hakimeh Ebrahimi Nik”